Transient osteoporosis of the hip following discontinuation of denosumab and switch to alendronate treatment

Osteoporos Int. 2024 Apr;35(4):741-743. doi: 10.1007/s00198-023-07000-5. Epub 2023 Dec 26.

Polyzois Makras^{1

2}, Maria P Yavropoulou^{3

4}, Athanasios D Anastasilakis⁵, Athanasios Papatheodorou³, Christos Tekedis⁶, Socrates E Papapoulos^{3

7}

¹ Department of Medical Research, 251 Hellenic Air Force & VA General Hospital, 3 Kanellopoulou St, 11525, Athens, Greece. pmakras@gmail.com.
² Department of Endocrinology and Diabetes, 251 Hellenic Air Force & VA General Hospital, Athens, Greece. pmakras@gmail.com.
³ Department of Medical Research, 251 Hellenic Air Force & VA General Hospital, 3 Kanellopoulou St, 11525, Athens, Greece.
⁴ Εndocrinology Unit, First Department of Propaedeutic and Internal Medicine, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
⁵ Department of Endocrinology, 424 General Military Hospital, Thessaloniki, Greece.
⁶ Department of Radiology, 251 Hellenic Air Force & VA General Hospital, Athens, Greece.
⁷ Center for Bone Quality, Department of Internal Medicine, Section Endocrinology, Leiden University Medical Center, Leiden, The Netherlands.

No abstract available

Publication types